期刊论文详细信息
Experimental Hematology & Oncology
Inhibition of transketolase by oxythiamine altered dynamics of protein signals in pancreatic cancer cells
Gary Guishan Xiao6  Robert Recker6  Yun Yen3  Qi Wang4  Vay Liang Go5  Yingchun Zhao6  Jing Xiao6  Wai-Nang Paul Lee5  Danjun Ma6  Xuemei Zhang1  Jiarui Wang2 
[1] The Medical College of Dalian University, Dalian Economic & Technological Development Zone, Dalian 116622, China;Department of Respiratory Medicine, The Fifth Hospital of Dalian, Dalian 116027, China;Molecular Clinical Pharmacology, City of Hope Cancer Center, Duarte, CA 90101, USA;Department of Respiratory Medicine, Dalian Medical University, Dalian 116027, China;Metabolomics Core, UCLA Center of Excellence in Pancreatic Diseases, Harbor-UCLA Medical Center, Torrance, CA 90502, USA;Genomics & Functional Proteomics Laboratories, Osteoporosis Research Center, Creighton University Medical Center, 601 N 30th ST, Suite 6730, Omaha, NE 68131, USA
关键词: Oxythiamine;    Transketolase;    Metabolic therapy;    Metabolic inhibitor;    Turnover rate;    Phosphorylation;    15 N stable isotope;    Pancreas cancer;    Quantitative proteomics;   
Others  :  812190
DOI  :  10.1186/2162-3619-2-18
 received in 2013-06-13, accepted in 2013-07-23,  发布年份 2013
PDF
【 摘 要 】

Oxythiamine (OT), an analogue of anti-metabolite, can suppress the nonoxidative synthesis of ribose and induce cell apoptosis by causing a G1 phase arrest in vitro and in vivo. However, the molecular mechanism remains unclear yet. In the present study, a quantitative proteomic analysis using the modified SILAC method (mSILAC) was performed to determine the effect of metabolic inhibition on dynamic changes of protein expression in MIA PaCa-2 cancer cells treated with OT at various doses (0 μM, 5 μM, 50 μM and 500 μM) and time points (0 h, 12 h and 48 h). A total of 52 differential proteins in MIA PaCa-2 cells treated with OT were identified, including 14 phosphorylated proteins. Based on the dynamic expression pattern, these proteins were categorized in three clusters, straight down-regulation (cluster 1, 37% of total proteins), upright “V” shape expression pattern (cluster 2, 47.8% total), and downright “V” shape pattern (cluster 3, 15.2% total). Among them, Annexin A1 expression was significantly down-regulated by OT treatment in time-dependent manner, while no change of this protein was observed in OT dose-dependent fashion. Pathway analysis suggested that inhibition of transketolase resulted in changes of multiple cellular signaling pathways associated with cell apoptosis. The temporal expression patterns of proteins revealed that OT altered dynamics of protein expression in time-dependent fashion by suppressing phosphor kinase expression, resulting in cancer cell apoptosis. Results from this study suggest that interference of single metabolic enzyme activity altered multiple cellular signaling pathways.

【 授权许可】

   
2013 Wang et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20140709080814230.pdf 1893KB PDF download
Figure 6. 61KB Image download
Figure 5. 50KB Image download
Figure 4. 72KB Image download
Figure 3. 49KB Image download
Figure 2. 90KB Image download
Figure 1. 77KB Image download
【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】
  • [1]Crabtree HG: Observations on the carbohydrate metabolism of tumours. Biochem J 1929, 23:3.
  • [2]Warburg OH: On the origin of cancer cells. Science 1956, 123:3191.
  • [3]Straussand LG, Conti PS: The applications of PET in clinical oncology. J Nucl Med 1991, 32:4.
  • [4]Lavayssièreemail R, Cabée AE, Filmont JE: Clinical applications of PET in oncology. Radiology 2004, 231:2.
  • [5]Maher JC, Krishan A, Lampidis TJ: Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol 2004, 53:2.
  • [6]Floridi A, Bruno T, Miccadei S, Fanciulli M, Federico A, Paggi MG: Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism. Biochem Pharmacol 1998, 56:7.
  • [7]Floridi A, Paggi MG, D’Atri S, De Martino C, Marcante ML, Silvestrini B, Caputo A: Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res 1981, 41:4661.
  • [8]Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P: Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005, 65:2.
  • [9]Ko YH, Pedersenemai PL, Geschwind JF: Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 2001, 173:1.
  • [10]Geschwind JF, Georgiades CS, Ko YH, Pedersen P: Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev Anticancer Ther 2004, 4:3.
  • [11]Boren J, Cascante M, Marin S, Comı́n-Anduix B, Centelles JJ, Lim S, Bassilian S, Ahmed S, Lee WNP, Boros LG: Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem 2001, 276:41.
  • [12]Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ: Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clin Cancer Res 2004, 10:19.
  • [13]Serkova NJ, Boros LG: Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications. Am J Pharmacogenomics 2005, 5:5.
  • [14]Raı̈s B, Comin B, Puigjaner J, Brandes JL, Creppy E, Saboureau D, Ennamany R, Lee WNP, Boros LG, Cascanteemal M: Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich’s tumor cells through inhibition of the pentose cycle. FEBS Lett 1999, 456:1.
  • [15]Comín-Anduix B, Boren J, Martinez S, Moro C, Centelles JJ, Trebukhina R, Petushok N, Lee WNP, Boros LG, Cascante M: The effect of thiamine supplementation on tumour proliferation. A metabolic control analysis study. Eur J Biochem 2001, 268:15.
  • [16]Pelicano H, Martin DS, Malt , Xu R-H, Huang P: Glycolysis inhibition for anticancer treatment. Oncogene 2006, 25:34.
  • [17]Boros LG, Puigjaner J, Cascante M, Lee WNP, Brandes JL, Bassiian S, Yusuf F, Williams RD, Muscarella P, Melvin WS, Schirmer WJ: Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res 1997, 57:19.
  • [18]Ramos-Montoya A, Lee WNP, Bassilian S, Lim S, Trebukhina RV, Kazhyna MV, Ciudad CJ, Noé V, Centelles JJ, Cascante M: Pentose phosphate cycle oxidative and nonoxidative balance: A new vulnerable target for overcoming drug resistance in cancer. Int J Cancer 2006, 119:12.
  • [19]Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A, Saavedra E: Energy metabolism in tumor cells. FEBS J 2007, 274:6.
  • [20]Rodríguez-Enríquez S, Vital-González PA, Flores-Rodríguez FL, Marín-Hernández A, Ruiz-Azuara L, Moreno-Sánchez R: Control of cellular proliferation by modulation of oxidative phosphorylation in human and rodent fast-growing tumor cells. Toxicol Appl Pharmacol 2006, 215:2.
  • [21]Romijn JC, Verkoelen CF, Schroeder FH: Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects. Prostate 1988, 12:1.
  • [22]Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:1-2.
  • [23]Zhang H, Cao R, Lee WN, Deng C, Zhao Y, Lappe J, Recker R, Yen Y, Wang Q, Tsai M, Go VL, Xiao GG: Inhibition of protein phosphorylation in MIA pancreatic cancer cells: confluence of metabolic and signaling pathways. J Proteome Res 2010, 9:2.
  • [24]Zhao Y, Lee WN, Lim S, Go VL, Xiao J, Cao R, Zhang H, Recker RR, Xiao GG: Quantitative proteomics: measuring protein synthesis using 15N amino acid labeling in pancreatic cancer cells. Anal Chem 2009, 81:2.
  • [25]Xiao GG, Nel AE, Loo JA: Nitrotyrosine-modified proteins and oxidative stress induced by diesel exhaust particles. Electrophoresis 2005, 26:1.
  • [26]Xiao GG, Wang M, Li N, Loo JA, Nel AE: Use of proteomics to demonstrate a hierarchical oxidative stress response to diesel exhaust particle chemicals in a macrophage cell line. J Biol Chem 2003, 278:50.
  • [27]Jiang XS, Tang LY, Cao XJ, Zhou H, Xia QC, Wu JR, Zeng R: Two-dimensional gel electrophoresis maps of the proteome and phosphoproteome of primitively cultured rat mesangial cells. Electrophoresis 2005, 26:23.
  • [28]Callister SJ, Barry RC, Adkins JN, Johnson ET, Qian WJ, Webb-Robertson BJM, Smith RD, Lipton MS: Normalization approaches for removing systematic biases associated with mass spectrometry and label-free proteomics. J Proteome Res 2006, 5:2.
  • [29]Ma D, Li S, Wang LS, Dai J, Zhao SL, Zeng R: Temporal and spatial profiling of nuclei-associated proteins upon TNF-alpha/NF-kappaB signaling. Cell Res 2009, 19:5.
  • [30]Chang C, Stewart RC: The two-component system. Regulation of diverse signaling pathways in prokaryotes and eukaryotes. Plant Physiol 1998, 117:3.
  • [31]Barford D, Das AK, Egloff MP: The structure and mechanism of protein phosphatases: insights into catalysis and regulation. Annu Rev Biophys Biomol Struct 1998, 27:133.
  • [32]Stock JB, Ninfa AJ, Stock AM: Protein phosphorylation and regulation of adaptive responses in bacteria. Microbiol Rev 1989, 53:4.
  • [33]Cozzone AJ: Protein phosphorylation in prokaryotes. Annu Rev Microbiol 1988, 42:97.
  • [34]Morrison DK: The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 2009, 19:1.
  • [35]Yuan Z, Becker EB, Merlo P, Yamada T, DiBacco S, Konishi Y, Schaefer EM, Bonni A: Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons. Science 2008, 319:5870.
  • [36]Tzivion G, Gupta VS, Kaplun L, Balan V: 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 2006, 16:3.
  • [37]Porter GW, Khuri FR, Fu H: Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Semin Cancer Biol 2006, 16:3.
  • [38]Pak JH, Moon JH, Hwang SJ, Cho SH, Seo SB, Kim TS: Proteomic analysis of differentially expressed proteins in human cholangiocarcinoma cells treated with Clonorchis sinensis excretory-secretory products. J Cell Biochem 2009, 108:6.
  • [39]Kang S, Shim HS, Lee JS, Kim DS, Kim HY, Hong SH, Kim PS, Yoon JH, Cho NH: Molecular proteomics imaging of tumor interfaces by mass spectrometry. J Proteome Res 2010, 9:2.
  • [40]Basu A, Banerjee H, Rojas H, Martine SR, Roy S, Jia Z, Lilly MB, De León M, Casiano CA: Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4. Prostate 2011, 71:7.
  • [41]Obeid M, Panaretakis T, Tesniere A, Joza N, Tufi R, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G: Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from “silent” to immunogenic. Cancer Res 2007, 67:17.
  • [42]Kolch W, Pitt A: Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer 2010, 9:618.
  • [43]Etienne-Manneville S: From signaling pathways to microtubule dynamics: the key players. Curr Opin Cell Biol 2010, 22:1.
  • [44]Zhang Z, Huang L, Zhao W, Rigas B: Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo. Cancer Res 2010, 70:6.
  • [45]Lim LHK, Pervaiz S: Annexin 1: the new face of an old molecule. FASEB J 2007, 21:4.
  • [46]Mussunoor S, Murray GI: The role of annexins in tumour development and progression. J Pathol 2008, 216:2.
  • [47]Lee WN, Guo P, Lim S, Bassilian S, Lee ST, Boren J, Cascante M, Go VL, Boros LG: Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor treatment. Br J Cancer 2004, 91:12.
  • [48]Xiao J, Lee WN, Zhao Y, Cao R, Go VL, Recker RR, Wang Q, Xiao GG: Profiling pancreatic cancer-secreted proteome using 15N amino acids and serum-free media. Pancreas 2010, 39:1.
  • [49]Zhao F, Mancuso A, Bui TV, Tong X, Gruber JJ, Swider CR, Sanchez PV, Lum JJ, Sayed N, Melo JV, Perl AE, Carroll M, Tuttle SW, Thompson CB: Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming. Oncogene 2010, 29:20.
  • [50]Chen J, Röcken C, Nitsche B, Hosius C, Gschaidmeier H, Kahl S, Malfertheiner P, Ebert MPA: The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression. Cancer Lett 2006, 233:2.
  • [51]Takayama Y, Kokuryo T, Yokoyama Y, Nagino M, Nimura Y, Senga T, Hamaguchi M: MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth. Cancer Lett 2008, 264:2.
  • [52]Mahalingam D, Giles F: Challenges in developing targeted therapy for pancreatic adenocarcinoma. Expert Opin Ther Targets 2008, 12:11.
  • [53]Riveraemail F, López-Tarruella S, Vega-Villegas ME, Salcedo M: Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev 2009, 35:4.
  • [54]Choi H, Chang J-W, Jung Y-K: Peroxiredoxin 6 interferes with TRAIL-induced death-inducing signaling complex formation by binding to death effector domain caspase. Cell Death Differ 2011, 18:3.
  • [55]Wang M, Xiao GG, Li N, Xie Y, Loo JA, Nel AE: Use of a fluorescent phosphoprotein dye to characterize oxidative stress-induced signaling pathway components in macrophage and epithelial cultures exposed to diesel exhaust particle chemicals. Electrophoresis 2005, 26:11.
  • [56]Zreiqat H, Howlett CR, Gronthos S, Hume D, Geczy CL: S100A8/S100A9 and their association with cartilage and bone. J Mol Histol 2007, 38:5.
  • [57]Mendonça G, Mendonça DBS, Aragão FJL, Cooper LF: The combination of micron and nanotopography by H(2)SO(4)/H(2)O(2) treatment and its effects on osteoblast-specific gene expression of hMSCs. J Biomed Mater Res A 2010, 94:1.
  • [58]Deng FY, Liu YZ, Li LM, Jiang C, Wu S, Chen Y, Jiang H, Yang F, Xiong JX, Xiao P, Xiao SM, Tan LJ, Sun X, Zhu XZ, Liu MY, Lei SF, Chen XD, Xie JY, Xiao GG, Liang SP, Deng HW: Proteomic analysis of circulating monocytes in Chinese premenopausal females with extremely discordant bone mineral density. Proteomics 2008, 8:20.
  • [59]Pratt JM, Petty J, Riba-Garcia I, Robertson DHL, Gaskell SJ, Oliver SG, Beynon RJ: Dynamics of protein turnover, a missing dimension in proteomics. Mol Cell Proteomics 2002, 1:8.
  • [60]Xiao GG, Garg M, Lim S, Wong D, Go VL, Lee WN: Determination of protein synthesis in vivo using labeling from deuterated water and analysis of MALDI-TOF spectrum. J Appl Physiol 2008, 104:3.
  • [61]Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:5930.
  文献评价指标  
  下载次数:120次 浏览次数:25次